Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.72 |
| ▸ | ACHE | P22303 | 8/20 | 0.46 |
| ▸ | RHEB | Q15382 | 3/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7546998 | 0.91 | CCR2 (0.62) | CCR2ACHERHEBSIGMAR1PRSS12 | |
| SCHEMBL7550694 | 0.90 | CCR2 (0.58) | CCR2ACHECHEK2HRH4KDM4E | |
| SCHEMBL7551037 | 0.90 | ACHE (0.59) | CCR2ACHECHEK2HRH4KDM4E | |
| SCHEMBL7160211 | 0.88 | CCR2 (0.54) | CCR2ACHERHEBPRSS12CHEK2 | |
| SCHEMBL7550103 | 0.85 | ACHE (0.56) | CCR2ACHEKDM4EALDH1A1GFER | |
| SCHEMBL7153825 | 0.84 | CCR2 (1.00) | CCR2ACHERHEBSIGMAR1PRSS12 | |
| SCHEMBL7549975 | 0.83 | CCR2 (0.55) | CCR2ACHESIGMAR1KDM4EMEN1 | |
| SCHEMBL7546108 | 0.83 | CCR2 (0.49) | CCR2ACHECHEK2KDM4EMEN1 | |
| SCHEMBL7547919 | 0.83 | AURKA (0.51) | CCR2ACHECHEK2KDM4EALDH1A1 | |
| SCHEMBL7550750 | 0.81 | CCR2 (0.49) | CCR2ACHESIGMAR1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020099054-A1 | 2-phenyl benzimidazole derivatives as MCP-1 antagonists | WARNER-LAMBERT COMPANY (US) | 2002-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099054-A1 | 2-phenyl benzimidazole derivatives as MCP-1 antagonists | CCR1, CCR2, CCR8 | CCR2 2/4885ACHE 4652/4885RHEB 4371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.